* The above product list shows our products which are approved by Hong Kong Department of Health only. It does not mean that all products are already placed in the market. For any product or business enquiries please contact us at ichk@ichk.org or (852) 2891 0581 for further details.

Dementia refers to decline in cognition in one or more domains e.g. learning and memory, language, executive function and social cognition. The most common neurodegenerative conditions are Alzheimer’s disease which mainly affect the elderly. Currently, there is no cure or disease modifying therapy. All the treatments available are for symptomatic relief only.

Acetylcholinesterase inhibitors
Acetylcholinesterase inhibitors exert their therapeutic action by inhibiting the degradation of acetylcholine and increasing cholinergic transmission. Most adverse events are cholinergic in nature, e.g. nausea, vomiting and diarrhea, that are generally mild and transient. Donepezil, Rivastigmine and Galantamine are indicated for the treatment of mild to moderately severe dementia of the Alzheimer type.

NMDA receptor antagonist
Memantine exerts moderate benefits in patients with moderate to severe dementia of the Alzheimer type. It is recommended in patients with moderate dementia only if acetylcholinesterase inhibitors are contraindicated or not responding.